Authoritative statistics from WHO show that in 2018, the number of newly diagnosed cancer patients worldwide reached 18.1 million, with 9.6 million having unfortunately succumbed to the disease. Lung cancer, known as the "silent killer," tops the charts in both incidence and mortality rates. Given that early symptoms of lung cancer are often hidden, most patients are diagnosed at the intermediate or even late stages, making surgical removal a daunting challenge. Against this backdrop, cryotherapy for Lungs has emerged as a distinctive choice for its minimally invasive, safe, and efficient treatment, spanning across the early, intermediate, and late stages of lung cancer, lighting up new hope for patients.
Cryotherapy for lungs, or cryoablation, cleverly utilizes the principle of low-temperature freezing. By swiftly lowering the temperature around the ablation needle with a cryogen, it induces the formation of ice crystals both inside and outside of tumor cells, leading to cell rupture, microvascular damage, and thrombosis, ultimately causing tumor cells to die in an ischemic and anoxic environment. This process is not only precise and efficient but also causes minimal damage to surrounding normal tissues.
Building on the profound foundation of traditional cryoablation, multi-modal cryoablation systems have emerged, with the Kangbo Knife being an outstanding representative. It perfectly combines low-temperature freezing with high-intensity heat ablation. Guided precisely by advanced imaging technologies like CT or ultrasound, the Kangbo Knife can easily penetrate the skin, delivering a super-micro composite probe with a diameter of only about 2mm accurately to the lung tumor area. It performs alternating cycles of -196°C extreme freezing and high temperatures above 80°C, physically destroying tumor cells. Compared to traditional cryoablation, the Kangbo Knife not only boasts significant efficacy and high safety but also effectively disrupts the tumor microvascular network, induces a strong immune response, and promotes cell apoptosis, further consolidating the treatment effect.
Non-Surgical Minimally Invasive Treatment
Cryotherapy for lungs eliminates the need for traditional surgical cuts, achieving treatment through local puncture with minimal trauma and rapid recovery.
Avoidance of General Anesthesia Risks
Most treatments require only local anesthesia, effectively avoiding potential complications such as airway obstruction that may arise from general anesthesia.
High Tolerance and Safety
The therapy has low risk and few complications, making it particularly suitable for patients who cannot undergo surgery or have high surgical risks, without causing systemic adverse reactions.
Rapid Recovery and Short Hospital Stay
Patients typically recover quickly after treatment, significantly reducing the length of hospital stay, with some even being discharged the next day.
Broad Applicability and Precise Treatment
It is not only compatible with lung cancer but also applicable to various tumor types; with imaging monitoring, it can accurately treat multiple nodules near vital organs in the lungs.
Immune Activation Effect
During cryoablation, the death of a large number of tumor cells releases antigens, thereby stimulating the body's immune response and adding new strength to the fight against cancer.
Especially worth mentioning is the Kangbo Knife, which employs multi-modal cryoablation systems. It retains the advantages of traditional cryoablation while significantly reducing the risk of bleeding and effectively avoiding the issue of tumor seeding along the needle tract, providing a safer and more effective treatment choice for lung cancer patients.
In summary, cryotherapy for lungs and its representative technology, the Kangbo Knife, are opening new paths for treating lung cancer and other solid tumors with their outstanding clinical performance and extensive application prospects, bringing hope and opportunities for rebirth to countless patients.
Hygea Medical Technology Co., Ltd.
Hygea Medical Technology Co., Ltd.
EN 
